European Journal of Internal Medicine
Volume 20, Issue 3 , Pages 232-235 , May 2009

Glucoregulation in type 2 diabetes: The lower the better? Glycosylated HbA1c of 6.5% seems to be the limit

  • I.M. Jazet

      Affiliations

    • Corresponding Author InformationCorresponding author. Department of General Internal Medicine, C4-R-73, Leiden University Medical Center, Albinusdreef 2, 2333 ZA Leiden, The Netherlands. Tel.: +31 71 5127227; fax: +31 71 5248140.
    • ,
  • A.E. Meinders

Received 10 July 2008 ,Accepted 1 August 2008.

References 

  1. Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care. 1993;16(2):434–444
  2. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med. 1998;339(4):229–234
  3. Sheetz MJ, King GL. Molecular understanding of hyperglycemia's adverse effects for diabetic complications. JAMA. 2002;288(20):2579–2588
  4. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998;352(9131):837–853
  5. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med. 1993;329(14):977–986
  6. Nathan DM, Cleary PA, Backlund JY, Genuth SM, Lachin JM, Orchard TJ, et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med. 2005;353(25):2643–2653
  7. Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000;321(7258):405–412
  8. Selvin E, Marinopoulos S, Berkenblit G, Rami T, Brancati FL, Powe NR, et al. Meta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus. Ann Intern Med. 2004;141(6):421–431
  9. Gerstein HC, Pogue J, Mann JF, Lonn E, Dagenais GR, McQueen M, et al. The relationship between dysglycaemia and cardiovascular and renal risk in diabetic and non-diabetic participants in the HOPE study: a prospective epidemiological analysis. Diabetologia. 2005;48(9):1749–1755
  10. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998;352(9131):854–865
  11. Kearney PM, Blackwell L, Collins R, Keech A, Simes J, Peto R, et al. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet. 2008;371(9607):117–125
  12. Standards of medical care in diabetes—2008. Diabetes Care. 2008;31(Suppl 1):S12–S54
  13. Effects of intensive glucose lowering in type 2 diabetes. The Action to Control Cardiovascular Risk in Diabetes Study Group. 358, 2545–59. 2008.
  14. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The ADVANCE Collaborative Group. 358, 2560–72. 2008.
  15. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004;351(13):1296–1305
  16. Gerstein HC, Mann JF, Yi Q, Zinman B, Dinneen SF, Hoogwerf B, et al. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA. 2001;286(4):421–426
  17. Kirkman MS, McCarren M, Shah J, Duckworth W, Abraira C. The association between metabolic control and prevalent macrovascular disease in type 2 diabetes: the VA Cooperative Study in diabetes. J Diabetes Complicat. 2006;20(2):75–80
  18. Despres JP, Lamarche B, Mauriege P, Cantin B, Dagenais GR, Moorjani S, et al. Hyperinsulinemia as an independent risk factor for ischemic heart disease. N Engl J Med. 1996;334(15):952–957
  19. Muis MJ, Bots ML, Bilo HJ, Hoogma RP, Hoekstra JB, Grobbee DE, et al. High cumulative insulin exposure: a risk factor of atherosclerosis in type 1 diabetes?. Atherosclerosis. 2005;181(1):185–192
  20. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med. 2007;356(24):2457–2471
  21. Pan NH, Lee TM, Lin MS, Huang CL, Chang NC. Association of gliclazide and left ventricular mass in type 2 diabetic patients. Diabetes Res Clin Pract. 2006;74(2):121–128
  22. Fava D, Cassone-Faldetta M, Laurenti O, De LO, Ghiselli A, De MG. Gliclazide improves anti-oxidant status and nitric oxide-mediated vasodilation in type 2 diabetes. Diabet Med. 2002;19(9):752–757
  23. Krumholz HM, Lee TH. Redefining quality—implications of recent clinical trials. N Engl J Med. 2008;358(24):2537–2539
  24. Gaede P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med. 2008;358(6):580–591
  25. Saydah SH, Fradkin J, Cowie CC. Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes. JAMA. 2004;291(3):335–342

PII: S0953-6205(08)00245-8

doi: 10.1016/j.ejim.2008.08.002

European Journal of Internal Medicine
Volume 20, Issue 3 , Pages 232-235 , May 2009

Article Tools